Skip to main content
Sister Publication Links
  • Rubber & Plastics News
Subscribe
  • My Account
  • LogIn
  • News
  • Technology Focus
    • Features
    • Technical Papers
    • Analysis: Rubber mixing plants of the future
      Analysis: US probes dumping by ESBR suppliers
      Opinion: Tire labels stuck in a rut
      Analysis: NR pricing takes one step forward, two steps back
    • Technical paper: Varying Si-substituents for rubber silanes
      White paper: Role of tire innerliners in improving 'in-use rolling resistance'
      White paper: Why tire air retention matters now more than ever
      Nippon Soda: Use of 1,2-polybutadiene in CSM rubber applications
  • Events
    • ERJ Events
    • ERJ Livestreams & Webinars
    • Industry Events
    • Journey to Automation Awards 2020
      Sustainability: Top 10 E4S projects table
  • Maps & Reports
  • People
  • Directory
  • Digital Edition
  • Brainiac
MENU
Breadcrumb
  1. Home
  2. News
April 12, 2005 12:00 AM

FDA reconsiders silicone breast implant ban

ERJ Staff
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print

    WASHINGTON (April 11)--The US Food and Drug Administration has convened a three-day hearing to hear testimony on whether the 13-year ban on silicone-gel breast implants should be lifted.

    Inamed Corp. and Mentor Corp., the last two US manufacturers of the devices, have petitioned the FDA for certification to sell them freely once again in the US.

    The issue of silicone implants is still an emotionally charged one in the US. On one hand, the devices are available in more than 60 countries, and studies from the National Academy of Sciences and other groups have largely discredited the charge that silicone gel causes autoimmune disease in women. On the other, the FDA said that perhaps three-quarters of all silicone implants will rupture over 10 years of use. Also, data from the National Cancer Institute suggest that women with silicone implants are twice as likely to develop malignant brain tumours and three times as likely to develop lung cancer as women who don't have the implants.

    The first day of the hearing will feature more than 12 hours of testimony from patients, doctors and lobbyists both for and against lifting the ban. The FDA advisory panel is expected to vote on Inamed's petition April 12 and Mentor's April 13.


    From Rubber & Plastics News

    RECOMMENDED FOR YOU
    Michelin targets 'around & beyond tires' in new strategy
    Michelin targets 'around & beyond tires' in new strategy
    Kuraray resumes production at Texas plants
    Kuraray resumes production at Texas plants
    BPF online event to study REACH post-Brexit
    BPF online event to study REACH post-Brexit
    Free Newsletters

    Breaking news and in-depth coverage of essential topics delivered straight to your inbox.

    Subscribe today

    Get the latest news impacting the European rubber industry, from breaking news to razor-sharp analysis, in print and online.

    Subscribe now
    Connect with Us
    • LinkedIn
    • Twitter
    • Youtube

    Logo
    Contact Us

    @ 2019 European Rubber Journal. 
    European Rubber Journal is published bi-monthly by NUERJ Ltd.

    Registered Office: Castle House, 89 High Street,
    Berkhamsted, Hertfordshire HP4 2DF, United Kingdom. 

    Tel. + 44 (0)203 196 0141 

    Registered No. 13104613 England

    Email: [email protected]bberjournal.com

    Website www.european-rubber-journal.com

    Customer service 

    Tel. + 44 (0)203 196 0141 

     

    Resources
    • About us
    • Contact Us
    • Advertise with Us
    • Media Kit
    • Ad Choices Ad Choices
    • Sitemap
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Copyright © 2021. NUERJ LTD. All Rights Reserved.
    • News
    • Technology Focus
      • Features
      • Technical Papers
    • Events
      • ERJ Events
      • ERJ Livestreams & Webinars
      • Industry Events
    • Maps & Reports
    • People
    • Directory
    • Digital Edition
    • Brainiac